Mavyret (glecaprevir and pibrentasvir), a treatment for adults and children with all genotypes of hepatitis C and compensated cirrhosis, shortens the duration of treatment to eight weeks
Mavyret (glecaprevir and pibrentasvir) tablets, have now been approved by the…